What is Oric?
Headquartered in South San Francisco, Oric Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to addressing the critical issue of therapeutic resistance in cancer treatment. By focusing on the molecular basis of disease, the company develops potent small molecule antagonists and inhibitors designed to improve patient outcomes where traditional therapies have failed. Its pipeline, which includes the glucocorticoid receptor antagonist ORIC-101 and CD73 inhibitors, positions the firm at the forefront of precision oncology. The company operates at the intersection of rigorous scientific discovery and strategic commercial development, leveraging deep expertise to navigate the complex regulatory and clinical landscapes of modern medicine.
How much funding has Oric raised?
Oric has raised a total of $383M across 6 funding rounds:
Series A
$15M
Series B
$53M
Series C
$50M
Series D
$55M
Share Placement
$85M
Stock/Share Issuance
$125M
Series A (2014): $15M with participation from Kravis Investment Partners
Series B (2015): $53M led by OrbiMed, Foresite Capital, EcoR1 Capital, The Column Group, and Topspin Partners
Series C (2018): $50M supported by Kravis Investment Partners, NS Investment, Foresite Capital, Fidelity Management & Research Company, Trinitas Capital Management, OrbiMed, Topspin Fund, TAIHO VENTURES, and Memorial Sloan Kettering Cancer Center
Series D (2019): $55M, investors not publicly disclosed
Share Placement (2023): $85M, investors not publicly disclosed
Stock/Share Issuance (2025): $125M with participation from Point72, Viking Global Investors, SR One, and Venrock
Key Investors in Oric
Point72
A private investment management firm that manages a number of private investment funds in long-short equity, quantitative equities and more.
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests.
SR One
A transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics.
What's next for Oric?
With the successful completion of its most recent financing, Oric Pharmaceuticals is well-positioned to scale its clinical operations and expand its research capabilities. The strategic focus will likely shift toward accelerating late-stage clinical trials and potentially broadening the scope of its pipeline to address additional resistance mechanisms. By maintaining a disciplined approach to capital deployment, the company aims to translate its scientific breakthroughs into viable therapeutic options, ultimately enhancing its market position and delivering long-term value to stakeholders. The continued support from top-tier life sciences investors suggests a clear path toward future commercialization and potential partnerships that could further validate its innovative approach to oncology.
See full Oric company page
